Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 1Approved for marketing 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 3

Conditions

Small Cell Lung Carcinoma 9Lung Neoplasms 3Bites and Stings 2Neuroendocrine Tumors 1Neuroendocrine Prostate Cancer 1Neoplasms 1Extensive Stage Small Cell Lung Cancer 1

Interventions

Carboplatin 345Cisplatin 240Paclitaxel 208Radiotherapy 206Pemetrexed 190Docetaxel 170Gemcitabine 158pembrolizumab 146Erlotinib Hydrochloride 111Magnetic Resonance Spectroscopy 101Etoposide 98Bevacizumab 96Specimen Handling 84Nivolumab 77durvalumab 73Radiosurgery 73Blood Specimen Collection 65Drug Therapy 61osimertinib 56Vinorelbine 54Gefitinib 50Surveys and Questionnaires 48atezolizumab 44Biopsy 43Irinotecan 42Radiation 41Topotecan 39Standard of Care 38Cyclophosphamide 38Surgical Procedures, Operative 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lung Neoplasms × AMG 757 × Clear all
NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

NCT04885998 2025-09-29

AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

Amgen

Phase 1 Completed
23 enrolled 21 charts
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06064500 2025-03-10

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

Amgen

Approved for marketing
Thoracic

Bites and Stings, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡